Dr. Furman on Current Treatment Options in CLL

Video

Richard R. Furman, MD, discusses current treatment options in chronic lymphocytic leukemia.

Richard R. Furman, MD, director, the CLL Research Center, Weill Cornell Medicine, member, the Lymphoma/Myeloma Service, the Division of Hematology/Oncology, discusses current treatment options in chronic lymphocytic leukemia (CLL).

Making treatment decisions for patients with relapsed/refractory CLL depends on prior frontline therapy, and how the patient tolerated and responded to that therapy, Furman says. For patients who have progressed on a BTK inhibitor, adding venetoclax (Venclexta) to the BTK inhibitor can create a synergistic effect and allow patients to receive the treatment prior to developing high tumor burdens and the risk of tumor lysis, Furman explains.

This option is particularly appealing for patients who progress on BTK inhibitors, since there is the risk of patients experiencing rapid progression with the discontinuation of the BTK inhibitor, Furman concludes.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH